News
| 13 November 2019 |
Verona Pharma to Present at Jefferies 2019 London Healthcare ConferenceLONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, will present a corporate… |
| 11 November 2019 |
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New YorkLONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Jan-Anders Karlsson, CEO of Verona Pharma, and Piers Morgan, CFO, will… |
| 5 November 2019 |
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019Reported positive Phase 2 data with dry powder inhaler formulation |
| 29 October 2019 |
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development UpdateLONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces that it will report its financial results for the three and nine mo… |
| 17 October 2019 |
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDLONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the… |
| 15 October 2019 |
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive symptom data from a Phase 2b trial with nebulized ensifent… |
| 19 September 2019 |
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present positive interim data from a Phase 2 trial with its dry powder inhal… |
| 9 September 2019 |
Holding(s) in Company TR-1: Standard form for notification of major holdingsLONDON, Sept. 09, 2019 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings |
| 3 September 2019 |
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment ConferenceLONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO, will present at the H.C. Wainwright 21st Annual… |
| 9 August 2019 |
Verona Pharma plc: PDMR DealingLONDON, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 8, 20… |
Innovative Therapies for Respiratory Care
See the 2017 Verona Pharma corporate video 2017
Runtime: 04:05
Basic & Clinical Pharmacology & Toxicology
Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD
The Lancet Respiratory Medicine
Peer-reviewed paper in the Lancet's highly-respected medication journal
Verona Pharma plc
3 More London Riverside,
London SE1 2RE
T: +44 (0)203 283 4200
E: info@veronapharma.com
© Verona Pharma plc 2019
